



Jimenez Diaz Foundation cordially invites you to the

GLOBAL NEURO SUMMIT 2011


5 March 2011, Madrid, Spain

Supported by an unrestricted educational grant from Merz Pharmaceuticals GmbH, Frankfurt, Germany

A welcome from the CHAIR

Dear colleagues,

On behalf of the Jimenez Diaz Foundation (University Autonoma of Madrid), I am delighted to invite you to attend the second Global Neuro Summit in Madrid, Spain, 5 March, 2011.



I look forward to coming together to learn about the latest evidence, advancements and opportunities in the treatment of movement disorders and dementia.

Alzheimer's disease is the most frequent neurodegenerative disorder and its prevalence will increase in the near future. Spasticity has an enormous socioeconomic impact, with an estimated prevalence rate of at least 20% after stroke. It is the most common cause of disease-related disability in adults.

Research in these fields is constantly advancing, allowing for better understanding of the disorders and improved treatments for patients. Therefore, we will discuss both the neuropharmacological and clinical aspects of the disorders.

The meeting program will include keynote lectures and interactive workshops in the areas of dementia and movement disorders given by an outstanding faculty of international speakers, providing an excellent forum to discuss and exchange knowledge and experiences with experts from around the globe. More than 500 participants are expected to attend the Global Neuro Summit, which is sponsored by Merz Pharmaceuticals, Germany.

Please join me for what promises to be a very engaging and informative event!

Pedro J Garcia-Ruiz – Associate Professor of Neurology

Coordinator of Movement Disorders Unit, Department of Neurology, Jimenez Diaz Foundation

Conference Venue: Melia Castilla Hotel, Calle del Capitán Haya 43, 28020 Madrid
www.meliacastilla.com/en

Meeting duration: 5 March 2011, 08:30 – 18:00

Program Summary GLOBAL NEURO SUMMIT 2011

5 March 2011

PLENARY SESSION

- Advances in the management of neurological disorders

DEMENTIA SESSION

- Diagnosing dementia and AD
- Treating AD patients
- Realistic outcomes in the treatment of AD – What can physicians expect?
- Managing expectations of patients and caregivers
- Workshops addressing the topics 'Scales', 'Treatment Options' and 'Combination Therapy'

Will run in parallel to Movement Disorder Session – with Focus on Spasticity

MOVEMENT DISORDER SESSION – WITH FOCUS ON SPASTICITY

- Obstacles and opportunities in the treatment of movement disorders
- The pathophysiology of spasticity
- Long-term treatment with botulinum toxin: evidence and challenges
- Developments in assessment of functional improvement in spasticity
- Interactive sessions: hands on experience in the management of complex cases, botulinum toxin injection techniques pros and cons

Will run in parallel to Dementia Session

Meeting language: English; simultaneous translation will be provided in French, German, Spanish

International faculty will include (in alphabetical order)

Alireza Atri (USA), Djamel Bensmail (France), Jens Bo Nielsen (Denmark), Juan-Carlos Martinez-Castrillo (Spain), Murat Emre (Turkey), Vjera Holthoff (Germany), Roy Jones (UK), Petr Kanovsky (Czech Republic), Pablo Martinez-Lage (Spain), Franco Molteni (Italy), Andreas Monsch (Switzerland), Pedro J Garcia-Ruiz (Spain), Lalith Satkunam (Canada), Philip Scheltens (Netherlands), David M. Simpson (USA), David Wilkinson (UK), Jörg Wissel (Germany), Stuart Yablon (USA)

 Capiro Fundación Jiménez Díaz

